Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years old
• People diagnosed with early-stage non-small cell lung cancer (Stage II to IIIA), confirmed by tissue testing, according to the AJCC 8th edition staging system
• People whose tumours have been assessed as suitable for surgical removal
• People whose primary (main) tumour has been assessed as suitable for a type of focused, high-dose radiation treatment called hypofractionated radiotherapy
• People whose tumour has tested negative for certain gene changes (EGFR, ALK, and ROS1 gene mutations)
• People who are generally well enough to carry out daily activities with little or no restriction (ECOG performance score of 0 or 1)
• People expected to live for more than one year
• People who have at least one tumour that can be measured on a scan, following standard measurement guidelines (RECIST 1.1)
• Women who could become pregnant must agree to use contraception during the study and for 3 months after it ends, and must have a negative pregnancy test within 7 days before joining; men must also agree to use contraception during the study and for 3 months after it ends
• People who are willing to take part voluntarily, sign a consent form, and are likely to follow the study requirements
• People assessed as suitable to join following a multi-disciplinary team (MDT) discussion — a review by a group of different medical specialists

Who may not be able to join:

• People whose primary tumour location has been assessed by a radiologist as not suitable for hypofractionated radiotherapy
• People diagnosed with small cell lung cancer, or a mixed tumour that contains small cell components
• People who have a history of, or are currently being treated for, another type of cancer
• People who have already received any cancer treatment, including chemotherapy, radiation, targeted therapy, or immunotherapy
• People whose scans (CT, MRI, or PET-CT) show the tumour is growing into major blood vessels, has unclear borders with blood vessels, or shows any hollow spaces or areas of tissue breakdown within the tumour
• People who have had coughing up blood, active bleeding, ulcers, a hole in the bowel, or a bowel blockage within the 3 months before joining
• People with a history of scarring or inflammation of the lung tissue (interstitial lung disease), or whose baseline CT scan shows a condition called idiopathic pulmonary fibrosis
• People with serious or poorly controlled conditions affecting the lungs, heart, liver, kidneys, or other body systems, including active infections, severe high blood pressure, unstable chest pain, or heart failure (confirm with trial site)
• People who have previously been treated with certain immune checkpoint drugs, including anti-PD-1, anti-PD-L1, anti-PD-L2, or similar immunotherapy agents (such as those targeting CTLA-4, OX-40, or CD137)
• People with uncontrolled fluid build-up in body cavities, such as large amounts of fluid around the lungs, in the abdomen, or around the heart
• People whose urine test shows significant levels of protein in the urine, or whose 24-hour urine protein is 1g or more, or who have serious liver or kidney problems
• People with uncontrolled high blood pressure (top number 140 mmHg or higher, or bottom number 90 mmHg or higher)
• People who have needed regular steroid medicines (such as prednisone at more than 10 mg per day) or other medicines that suppress the immune system within 14 days before starting the trial
• People who have had a blood clot, stroke, brain bleed, or similar blood vessel event within the 6 months before joining
• People who have had major surgery or a serious injury within 28 days before joining
• Women who are pregnant or breastfeeding
• People considered unsuitable for other reasons, based on the judgement of the trial investigators

Important: Always verify eligibility with the trial site directly before applying.